Logo image of CTXR

CITIUS PHARMACEUTICALS INC (CTXR) Stock Fundamental Analysis

NASDAQ:CTXR - US17322U3068 - Common Stock

1.29 USD
-0.04 (-3.01%)
Last: 9/2/2025, 4:30:02 PM
1.27 USD
-0.02 (-1.55%)
After Hours: 9/2/2025, 4:30:02 PM
Fundamental Rating

2

Overall CTXR gets a fundamental rating of 2 out of 10. We evaluated CTXR against 195 industry peers in the Pharmaceuticals industry. CTXR may be in some trouble as it scores bad on both profitability and health. CTXR is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTXR has reported negative net income.
CTXR had a negative operating cash flow in the past year.
CTXR had negative earnings in each of the past 5 years.
CTXR had a negative operating cash flow in each of the past 5 years.
CTXR Yearly Net Income VS EBIT VS OCF VS FCFCTXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CTXR's Return On Assets of -32.10% is in line compared to the rest of the industry. CTXR outperforms 49.23% of its industry peers.
CTXR's Return On Equity of -63.01% is in line compared to the rest of the industry. CTXR outperforms 48.72% of its industry peers.
Industry RankSector Rank
ROA -32.1%
ROE -63.01%
ROIC N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
CTXR Yearly ROA, ROE, ROICCTXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTXR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTXR Yearly Profit, Operating, Gross MarginsCTXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for CTXR has been increased compared to 1 year ago.
Compared to 5 years ago, CTXR has less shares outstanding
There is no outstanding debt for CTXR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTXR Yearly Shares OutstandingCTXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CTXR Yearly Total Debt VS Total AssetsCTXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.63, we must say that CTXR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.63, CTXR perfoms like the industry average, outperforming 44.62% of the companies in the same industry.
CTXR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CTXR has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -3.63
ROIC/WACCN/A
WACCN/A
CTXR Yearly LT Debt VS Equity VS FCFCTXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CTXR has a Current Ratio of 0.47. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTXR has a Current ratio of 0.47. This is amonst the worse of the industry: CTXR underperforms 93.85% of its industry peers.
CTXR has a Quick Ratio of 0.47. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTXR has a Quick ratio of 0.14. This is amonst the worse of the industry: CTXR underperforms 95.90% of its industry peers.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.14
CTXR Yearly Current Assets VS Current LiabilitesCTXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

CTXR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.70%.
EPS 1Y (TTM)-71.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CTXR will show a very strong growth in Earnings Per Share. The EPS will grow by 22.16% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.42%
EPS Next 2Y44.34%
EPS Next 3Y36.09%
EPS Next 5Y22.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTXR. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 3.51, the valuation of CTXR can be described as very cheap.
CTXR's Price/Forward Earnings ratio is rather cheap when compared to the industry. CTXR is cheaper than 97.95% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.76, CTXR is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.51
CTXR Price Earnings VS Forward Price EarningsCTXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTXR Per share dataCTXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

CTXR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTXR's earnings are expected to grow with 36.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.34%
EPS Next 3Y36.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTXR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (9/2/2025, 4:30:02 PM)

After market: 1.27 -0.02 (-1.55%)

1.29

-0.04 (-3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)12-26 2025-12-26/amc
Inst Owners7.27%
Inst Owner Change46.54%
Ins Owners4.41%
Ins Owner Change0%
Market Cap21.94M
Analysts80
Price Target5.1 (295.35%)
Short Float %3.99%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-128.87%
Min EPS beat(2)-224.81%
Max EPS beat(2)-32.93%
EPS beat(4)0
Avg EPS beat(4)-95.7%
Min EPS beat(4)-224.81%
Max EPS beat(4)-4.05%
EPS beat(8)1
Avg EPS beat(8)-102.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-23.08%
PT rev (3m)-28.57%
EPS NQ rev (1m)-64.04%
EPS NQ rev (3m)-139.35%
EPS NY rev (1m)-11.96%
EPS NY rev (3m)-444.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.12%
Revenue NY rev (1m)-51.04%
Revenue NY rev (3m)-51.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.51
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.96
EYN/A
EPS(NY)0.37
Fwd EY28.47%
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0
BVpS3.82
TBVpS-2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.1%
ROE -63.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.14
Altman-Z -3.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y15.42%
EPS Next 2Y44.34%
EPS Next 3Y36.09%
EPS Next 5Y22.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28%
OCF growth 3YN/A
OCF growth 5YN/A